Calyx Pharma

Executive Summary

Calyx Pharma, founded in 2020 in Mumbai, India, is a preclinical-stage biotechnology startup leveraging a proprietary small-molecule discovery platform to develop novel therapeutics for oncology and immunology. The company integrates advanced computational chemistry and high-throughput screening to identify candidate drugs targeting unmet medical needs. As a private, early-stage entity, Calyx Pharma is positioned within India's growing biotech ecosystem but faces significant risks typical of preclinical companies, including high capital requirements, lengthy development timelines, and regulatory hurdles. The company has no disclosed pipeline, revenue, or funding details, underscoring its nascent stage. However, its focus on validated areas like oncology and immunology, combined with a technology-driven approach, provides a potential pathway for differentiation if lead candidates demonstrate preclinical promise.

Upcoming Catalysts (preview)

• Q3 2026Completion of lead optimization for lead program35% success
• Q1 2027Initiation of IND-enabling studies30% success
• TBDPotential licensing or partnership agreement25% success